Sexual issues a major concern for cancer patients taking new targeted drugs

Oct 12, 2010

New drugs that target specific molecular mechanisms of cancer have improved the treatment of cancer patients in recent years, but those benefits may come with a cost to the patient's sex life, researchers have found.

At the 35th Congress of the European Society for Medical Oncology (ESMO) in Milan, Italy, French researchers reported on one of the few studies to investigate the impact of on the sexual functioning of patients.

Dr Yohann Loriot and Dr Thomas Bessede from Institut Gustave Roussy in Villejuif, France and colleagues found that patients taking targeted therapies had significantly decreased levels of sexual function and satisfaction.

"The new molecular targeted therapies have been available for 6 or 7 years and researchers and physicians have observed some new side-effects not often reported with chemotherapy such as cutaneous side-effects and gastro-intestinal toxicity. But very few studies have been conducted in the field of sexuality, mainly because patients are not willing to talk with their physicians on this topic," Dr Loriot said.

The researchers surveyed 51 patients (40 men and 11 women) who had been taking molecular targeted therapies for more than three months without progressive disease about changes in their sexual life.

The drugs involved were sunitinib, sorafenib, temsirolimus, everolimus, bevacizumab, tarceva and .
Men completed the International Index of Erectile Function (IEEF) questionnaire --which includes questions on erectile function, intercourse satisfaction, orgasmic function, and overall satisfaction.

Women in the study completed the Female Sexual Function Index (FSFI) questionnaire, which includes questions on desire, arousal, lubrication, orgasm, satisfaction and pain.

The median overall IIEF score for men was 40, just 53% of the maximum score. For women, the median FSFI score was 8.4, just 24% of the maximum.

"The sex lives of the patients in our study had reduced quality and intensity," Dr Loriot said. "We also found that more than half of the patients expressed a wish for a satisfying sexuality, but many of them found it difficult to initiate a discussion on the topic with their doctors."

The impact of treatment on the sexuality of is poorly understood, and is generally not considered in clinical trials of treatments, Dr Loriot said.

"Oncologists can address this issue first by assessing this concern more often in clinical trials, and by talking with their patients about it," he said.

He suggested that oncologists could offer patients an assessment for sexual disorders during their treatment course, establish an outpatient clinic to deal with sexual disorders, or, if needed, refer patients to a specialist.

Sexuality is a major concern for cancer patients, as it is for everyone, noted Professor Raphael Catane, Chair of the department of oncology at Sheba Medical Center in Tel Hashomer, Israel. "The disease itself, and frequently its therapy, may have a major detrimental effect on the patient's sex life. It is hoped that the new biological/targeted treatments would be less injurious to the sexual life of cancer patients. "

"The study by this French group has taken an important step toward understanding the effect of biological/targeted treatments on sexuality," Prof Catane said. "They meticulously reviewed the sexual function of their patients receiving biological agents. The results show a diminished sexual drive and pleasure, but the degree and the duration, and how it compares to the standard/conventional therapy, is not yet known. This study can be a basis for further investigation of this very important aspect of cancer therapy."

Explore further: Early hormone therapy may be safe for women's hearts

Provided by European Society for Medical Oncology

5 /5 (1 vote)
add to favorites email to friend print save as pdf

Related Stories

Cancer of Any Type Can Cause Prolonged Sexual Dysfunction

Apr 02, 2010

(PhysOrg.com) -- Cancer often leads to significant and long-term disruption in sexual function and intimacy, regardless of the type of cancer or how far along the patient is in the treatment plan, according to a new study ...

Men experience sexual dysfunction during hepatitis C therapy

Sep 01, 2009

Sexual impairment is common among men with chronic hepatitis C undergoing antiviral therapy, according to a new study in Gastroenterology, the official journal of the American Gastroenterological Association (AGA) Instit ...

Cialis aids prostate cancer sex function

Oct 02, 2006

Dutch scientists say they have found a drug usually prescribed for erectile dysfunction in men increases the sexual function of prostate cancer survivors.

Recommended for you

Cancer: Tumors absorb sugar for mobility

1 hour ago

Cancer cells are gluttons. We have long known that they monopolize large amounts of sugar. More recently, it became clear that some tumor cells are also characterized by a series of features such as mobility or unlikeliness ...

Early hormone therapy may be safe for women's hearts

10 hours ago

(HealthDay)—Healthy women at low risk of cardiovascular disease may be able to take hormone replacement therapy soon after menopause for a short time without harming their hearts, according to a new study.

Low yield for repeat colonoscopy in some patients

11 hours ago

(HealthDay)—Repeat colonoscopies within 10 years are of little benefit to patients who had no polyps found on adequate examination; however, repeat colonoscopies do benefit patients when the baseline examination was compromised, ...

Cell's recycling center implicated in division decisions

14 hours ago

Most cells do not divide unless there is enough oxygen present to support their offspring, but certain cancer cells and other cell types circumvent this rule. Researchers at The Johns Hopkins University have now identified ...

User comments : 1

Adjust slider to filter visible comments by rank

Display comments: newest first

junkd
not rated yet Nov 22, 2010
It s the solution!
www.star-of-healt..._id=5831